ViroPharma Inc. 730 Stockton Drive Exton,
PA 19341 United States - Map Phone: 610-458-7300 Fax: 610-458-7380 Website: http://www.viropharma.com
ViroPharma Incorporated, a biotechnology company, develops and commercializes therapeutic products that address serious diseases in the United States and internationally. The company markets and sells Cinryze, a C1 esterase inhibitor therapy for the routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema, a life-threatening genetic disorder; and Vancocin HCl capsule, an oral capsule formulation for the treatment of C. difficile-associated diarrhea (CDAD) and to treat enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. It also offers Plenadren, an orphan drug for treatment of adrenal insufficiency in adults; and Buccolam, an oromucosal solution for treatment of prolonged, acute, and convulsive seizures in infants, toddlers, children, and adolescents. The company’s development programs include Cinryze, a C1 esterase inhibitor for management of hereditary angioedema; maribavir for cytomegalovirus infection; and VP 20621, a non-toxigenic strain of C. difficile for the treatment and prevention of CDAD. Its clinical stage drug candidate comprises VP-20629 for the treatment of Friedreich’s Ataxia. The company sells its products directly to wholesale drug distributors and specialty pharmacies/distributors. It has a license agreement with GlaxoSmithKline to develop and commercialize maribavir, an antiviral compound. ViroPharma Incorporated was founded in 1994 and is headquartered in Exton, Pennsylvania. Key Statistics
| |
| ViroPharma Inc.’s ISS Governance QuickScore as of Jun 1, 2013 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 3; Compensation: 1. | | Brought to you by Institutional Shareholder Services (ISS) |
| | Pay | Exercised | Mr. Vincent J. Milano ,
49 Chairman, Chief Exec. Officer and Pres | 939.00K | 2.12M | Mr. Charles A. Rowland Jr., CPA, MBA,
54 Chief Financial Officer and VP | 573.00K | 2.08M | Mr. Daniel B. Soland ,
54 Chief Operating Officer, Chief Commercial Officer and VP | 714.00K | 807.00K | Dr. Colin Broom M.D.,
57 Chief Scientific Officer and VP | 584.00K | 1.36M | Mr. Robert G. Pietrusko Pharm. D.,
64 VP of Global Regulatory Affairs & Quality | 580.00K | 422.00K |
|
| | Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|